TAS-120 helps the patients in becoming resistant to BGJ398 and FGFR2 mutations.
Anti-tumor activity has been observed in the patient with intrahepatic cholangiocarcinoma (ICC) that activates ATP-competitive fibroblast growth factor receptor gene fusions. This results in resistance and results in the development of mutation of FGFR2 kinase.
It was further reported in 4 patients with FGFR2 that they developed Debio 1347. It was due to the activation of TAS-120 that fight the FGFR2.TAS-120 is the inhibitor of FGFR and it is irreversible. In patients with FGFR2, an increase in the duration of FGFR inhibition, FGFR inhibitors can be sequenced in a planned manner along with the biopsy.
TAS-120 helps the patients in becoming resistant to BGJ398 and FGFR2 mutations.
To know more about mutation, refer to the below link:
brainly.com/question/9598940
#SPJ4
